BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder Jul 18, 2023
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting Mar 7, 2023
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data Feb 23, 2023
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors Jan 24, 2023
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Jan 19, 2023
BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States Dec 7, 2022
BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc. Nov 22, 2022
